Survivorship Bias: The Hidden Flaw in Your Investment Research That Makes Every Strategy Look Like a Guaranteed Winner

During World War II, the US military faced a critical problem: their bombers were being shot down at an alarming rate. Engineers studied the returning planes, mapped every bullet hole, and prepared to armour the most damaged areas.

Then a statistician named Abraham Wald asked a question that changed everything: “What about the planes that didn’t return?”

The planes that survived came back with bullet holes in the wings and fuselage — but none in the engine. The obvious conclusion was to reinforce the wings. But Wald realised the truth was the exact opposite: planes got shot in the engine too — those just never made it back. The military was only looking at survivors.

This insight — known as Survivorship Bias — is one of the most dangerous and most ignored flaws in how Indian investors analyse stocks, evaluate strategies, and make investment decisions. And if you don’t understand it, you are almost certainly making costly mistakes right now.

What Is Survivorship Bias?

Survivorship bias is a logical error where you concentrate only on the subjects that “survived” some selection process — while ignoring those that did not. The survivors are visible. The failures are invisible. This creates a deeply distorted picture of reality.

In investing, survivorship bias shows up everywhere:

• When you study “multibagger stocks” — you only see the winners, not the 90% that went nowhere or went to zero
• When you evaluate mutual fund track records — the funds that underperformed were merged or shut down; you only see surviving funds with good records
• When you backtest a strategy — historical databases don’t include companies that were delisted, went bankrupt, or were acquired; so every strategy “works” in backtesting
• When you read success stories — you hear about legendary investors’ 1000x gains but not about the investors who applied similar logic and lost everything

The Real Scale of Survivorship Bias in Indian Markets

Here is a number that should shock you: according to research published in 2025 on India’s NIFTY Smallcap 250 index, 82.5% of all stocks that were ever in this index are no longer in it. Of those removed: 16.1% were outright delisted (many due to fraud or business failure), 33.1% “graduated” to larger caps (these are the success stories you hear about), and 33.2% were simply demoted for poor performance.

Think about what this means. When you look at today’s Nifty Smallcap 250 and study its historical performance, you are looking at only the 17.5% of companies that survived the full journey. The other 82.5% — including the bankruptcies, the frauds, the chronic underperformers — are invisible in the data.

This is precisely why small-cap investing looks so attractive in backtests and so dangerous in reality.

How Survivorship Bias Distorts Nifty 50 Analysis

Let’s take India’s most prestigious index: the Nifty 50. Today, it features companies like Reliance, HDFC Bank, Infosys, and TCS — representing India’s finest businesses. But this index has been continuously rebalanced for decades.

Companies like Yes Bank, Suzlon Energy, and JP Associates were once prominent Nifty 50 members. They represented “India’s top 50 companies.” Yes Bank lost over 90% of its value before being rescued by the government. Suzlon went from being a renewable energy darling to facing bankruptcy. JP Associates, once a blue-chip infrastructure giant, is today a shadow of its former self.

When you look at the Nifty 50’s historical returns and say “see how well Indian large-caps have performed over 20 years,” you are ignoring the fact that the composition of that index changed dramatically — underperformers were removed and replaced with winners. The index survived; many of its original constituents did not.

The Mutual Fund Trap

Here is another manifestation of survivorship bias that most Indian investors never think about. India has over 1,500 mutual fund schemes — but many schemes that existed 15 years ago have been quietly merged into better-performing funds or discontinued entirely.

When a fund company shows you “average returns of equity funds over 15 years,” they are calculating the average using only funds that survived 15 years. The funds that performed poorly enough to be merged or shut down are excluded. This mathematically inflates the “average” performance that investors use to benchmark their expectations.

Research has consistently found that adjusting for survivorship bias in mutual fund data typically reduces reported performance by 1 to 3 percentage points per year. In compounding terms over decades, that is an enormous gap between perception and reality.

The Backtesting Illusion: Why Every Strategy “Works” on Paper

This is perhaps the most dangerous manifestation of survivorship bias for serious investors. Backtesting means applying an investing strategy to historical data to see how it would have performed.

The problem: most historical stock databases only include companies that currently exist. If a company went bankrupt in 2012, it does not appear in today’s database. So when you backtest a “buy low P/E stocks” strategy, your database automatically excludes all the low P/E stocks that went bankrupt — precisely because they were cheap for a reason. Your strategy looks brilliant. In reality, you would have bought some of those companies and suffered massive losses.

The 2025 SSRN research on Indian small-caps specifically found that survivorship bias is more severe in emerging markets like India because of “higher portfolio turnover and corporate volatility amplifying bias effects relative to developed markets.” This is critically important — India is not a mature market where survivorship bias is modest. In Indian small-caps, it is extreme.

The Entrepreneur Fallacy: Why Success Stories Are Misleading

We celebrate legendary Indian entrepreneurs as proof that building a business from scratch into a listed company is a path to extraordinary wealth. These stories are real and inspiring.

But we rarely hear about the tens of thousands of entrepreneurs who started similar businesses, worked just as hard, and failed — either never reaching a listing, or listing and then losing everything for their shareholders. The successes are visible. The failures are invisible.

This creates a misleading impression about the “base rate” of investment outcomes. When you hear “I invested in a small-cap 10 years ago and made 100x,” you are hearing a survivor’s story. For every such story, there are dozens of investors who held small-caps that went from Rs 100 to Rs 5.

How to Correct for Survivorship Bias in Your Investing

Understanding survivorship bias does not mean becoming paralysed or pessimistic. It means investing with clear eyes. Here is how to practically counteract it:

1. Study failures as rigorously as successes. Before investing in a sector, research companies in that sector that failed. What did they have in common? What early warning signs were present? This creates a more complete picture of the risk landscape.

2. Focus on business quality, not past price performance. A stock that has already risen 500% is a survivor — but whether it continues rising depends on the underlying business quality, not its track record. Evaluate current fundamentals: profitability, cash generation, debt levels, and competitive positioning.

3. Be deeply sceptical of backtested strategies. The best protection is to understand WHY a strategy should work, not just that it worked on historical data. A strategy grounded in durable economic logic — buying quality businesses at fair prices — is more reliable than one that merely “worked” in a backtest.

4. Demand full track records, including losing periods. When evaluating any fund or advisory service, ask for the complete history including periods of underperformance. A track record without drawdown data is a survivor’s track record.

5. Invest in businesses with structural advantages, not just good recent performance. Quality businesses with consistent earnings growth, strong return on capital, low debt, and competitive moats are less likely to become part of the invisible graveyard of failures.

Titan Biotech: A Quality Compounder That Stands Out

As of this writing, Indian markets are closed for Mahavir Jayanti (March 31, 2026) — a day of reflection that is fitting for this topic. The last trading session (March 30, 2026) saw the SENSEX close at 71,947.55 (down 1,635 points, -2.22%) and the NIFTY 50 at 22,331.40 (down 488 points, -2.14%). This fiscal year-end weakness offers a useful reminder: markets fluctuate, but business quality endures.

In this environment, it is worth highlighting a company that demonstrates what genuine business quality looks like — one that is less vulnerable to becoming a survivorship bias statistic.

Titan Biotech Ltd (BSE: 524717) is currently trading at Rs 458 — which is also its 52-week high, reflecting the market’s growing recognition of its quality. Market cap stands at Rs 1,891 Crore, with a P/E of 69.5, ROCE of 16.9%, and ROE of 15.0%. The stock has risen from a 52-week low of Rs 74.7 (pre-split equivalent adjusted) — a testament to the compounding power of quality business fundamentals.

Titan Biotech operates in the specialised biochemical segment — supplying bacteriological and pharmaceutical culture media, enzymes, and biochemicals to research labs, pharmaceutical companies, and institutions across India and globally. This is a niche with high entry barriers, consistent demand, and recurring customers. The business generates returns on capital above its cost of capital — the fundamental hallmark of a quality compounder.

This is the type of business that is less likely to appear in the “failures” column of the survivorship bias ledger — because it is built on real, recurring revenue, genuine product differentiation, and a market that will continue to grow as India’s pharmaceutical and research sectors expand.

The F&O Warning: The Ultimate Survivorship Bias Trap

Futures and Options trading is the single worst manifestation of survivorship bias in Indian markets. Every F&O “success story” you see on YouTube, WhatsApp, or social media is a survivor. You do not hear from the 90% who lost money.

SEBI’s own study found that 9 out of 10 individual traders in the equity F&O segment incurred net losses. If you participate in F&O trading, you have a 90% probability of losing money — not because you are not smart enough, but because the structure of derivatives is inherently weighted against retail participants.

The success stories you see are survivorship bias in action. For every trader who made Rs 10 lakh from options in one month, there are 9 more who lost Rs 10 lakh and quietly disappeared from the social media landscape.

Focus instead on what actually works: quality stock picking, long-term holding, and the compounding of genuine business value. This is not exciting. It does not make for viral content. But it works — and the evidence is not survivorship-biased, because the strategy is grounded in economic logic, not pattern-matching to lucky outcomes.

Key Takeaways

Survivorship bias is invisible by definition — you can only see the survivors. The failures quietly disappear from the data. This makes every strategy look better than it is, every market look more reliable than it is, and every success story more replicable than it is.

The antidote is quality. Invest in businesses with genuine competitive advantages, consistent profitability, and honest management. Study failures as much as successes. Demand complete track records. And stay far away from F&O — the most survivorship-biased arena in all of Indian finance.

To go deeper on value investing principles, watch our complete Value Investing Course Playlist on YouTube — completely free.

SEBI Disclaimer: 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses according to a SEBI study. F&O trading is essentially gambling. Focus on quality stock picking and long-term value investing instead.

Disclaimer: The author (Manish Goel) is a SEBI Registered Research Analyst (Registration No. INH100004775) and Multibagger Shares (Multibagger Securities Research & Advisory Pvt. Ltd.) is a SEBI Registered Investment Advisor (Registration No. INA100007736). This post is for educational purposes only and should not be construed as a buy/sell recommendation. Please do your own research and consult a qualified financial advisor before making investment decisions. Stock market investments are subject to market risks. Past performance is not indicative of future results.

Manish Goel

Manish Goel is a Chartered Accountant, SEBI-registered Investment Advisor, and founder of Multibagger Shares. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

See Full Bio